Pharmaceutical companies use analytics at nearly every stage of their business, from identifying promising drug molecules to tracking how patients respond to medications years after launch. Data science and machine learning have become core tools that shape which drugs get developed, how clinical trials run, which doctors hear about new treatments, and how supply chains keep sensitive products moving safely. Here’s how analytics works across each of these areas.
Finding New Drug Candidates Faster
Drug discovery has traditionally been slow and expensive, often taking a decade or more to move from a molecular concept to an approved treatment. Analytics is compressing that timeline significantly. In protein drug development, generative biology (a branch of AI that designs new biological molecules) has helped cut antibody discovery times in half, according to researchers at Harvard’s Wyss Institute.
One of the biggest challenges in early-stage research is narrowing down which molecules are worth testing in the lab. The number of possible chemical compounds is astronomical, and testing each one physically is impractical. Reinforcement learning, a type of AI that optimizes toward a defined goal, helps researchers shrink that enormous solution space to a manageable set of candidates. Rather than screening thousands of compounds through costly lab experiments, computational models predict which ones are most likely to work, so scientists can focus their bench time on the strongest options.
This approach is especially valuable for diseases where funding is limited and patient need is high. Computational screening provides a lower-cost way to identify promising compounds before committing to expensive lab testing. Companies like Talus Bio are applying custom AI models to go after traditionally “undruggable” targets like transcription factors, proteins that were previously too difficult to design drugs against. Their platform blends proprietary data with pre-trained models for proteins and chemistry, iterating and improving as new experimental results come in.
Optimizing Clinical Trials
Clinical trials are one of the most resource-intensive parts of bringing a drug to market, and recruiting enough of the right patients is consistently the biggest bottleneck. Enrolling a mid-stage trial can take up to 18 months. Machine learning models have the potential to cut that timeline roughly in half by identifying eligible patients more efficiently.
One concrete method: AI tools that mine electronic health records (EHRs) to find patients who match a trial’s eligibility criteria. One study found that using AI to scan EHR data improved enrollment rates from 0.17 to 0.32 patients per screening day, nearly doubling the pace. Pre-screening tools, such as online surveys linked to social media ads, help identify strong candidates before they ever visit a trial site, saving staff significant time on unnecessary screening tests.
Analytics also plays a role in choosing where trials happen. Companies run feasibility assessments on potential clinical sites, evaluating factors like the site’s experience with similar therapeutic areas, its equipment and data management capabilities, its regulatory readiness, and whether it can meet Good Clinical Practice standards. Rather than defaulting to large urban academic medical centers, sponsors increasingly use data to select a mix of urban and community-based locations. This broadens the geographic reach of recruitment and helps enroll a more diverse patient population, which is increasingly important for both scientific validity and regulatory expectations.
A newer tactic is “just-in-time” site activation, where a clinical site is brought online only when analytics identify eligible patients nearby. This is particularly useful for trials targeting rare genetic profiles or uncommon disease subtypes, where waiting for patients to show up at a pre-selected site could mean months of empty enrollment slots.
Managing the Supply Chain
Pharmaceutical supply chains are unusually complex. Products often require strict temperature control, supplier networks are fragmented across multiple countries, and some shipments (like tissue samples or cell therapies) are literally irreplaceable. The margin for error is thin.
To manage this, supply chain teams are shifting from manual oversight to automated, predictive systems sometimes called “control centers.” These platforms use machine learning to forecast demand, flag potential disruptions before they happen, and benchmark performance across suppliers. Rather than reacting to a stockout or a temperature excursion after the fact, predictive models can identify patterns that signal trouble ahead, like a supplier whose lead times are gradually creeping up or a shipping lane with increasing temperature deviations.
The shift is driven partly by pressure to do more with less. Supply chain leaders are being asked to maintain or improve reliability while controlling costs, and automation is the primary lever. Organizations are moving beyond simply collecting data to actively using benchmarking and machine learning tools that turn logistics data into operational decisions.
Targeting Physicians and Sales Teams
Once a drug reaches the market, pharmaceutical companies use commercial analytics to decide which doctors to reach, through which channels, and with what messaging. Customer segmentation algorithms analyze prescription patterns, patient populations, and physician behavior to identify doctors who serve patients fitting a drug’s target profile. These models can predict, with meaningful accuracy, which physicians are likely to prescribe a new drug, switch patients from a competitor’s product, or stick with their current treatment.
Analytics also identifies how individual doctors prefer to be contacted. Some respond better to in-person visits from sales representatives, others to digital channels, and many have strict limits on how often they’ll engage. With physician access significantly more restricted than it was a decade ago, companies use these insights to design interactions that are tailored, relevant, and timed to the doctor’s preferences. The result is fewer wasted touchpoints and higher engagement.
Beyond physician-level targeting, analytics shapes broader commercial strategy. Pricing, messaging, and sales team targets are refined based on data about past transactions, prescribing behavior, and the needs of different players in the healthcare ecosystem, including insurers, hospital systems, and pharmacy benefit managers.
Tracking Patient Adherence
Getting a prescription written is only part of the equation. Pharmaceutical companies also use analytics to understand whether patients are actually taking their medications as directed. Poor adherence is a massive problem across healthcare: patients skip doses, abandon prescriptions early, or never fill them at all. This hurts patient outcomes and, from the company’s perspective, reduces revenue.
Companies run health advocacy and wellness programs designed to keep patients engaged with their treatment. Integrated business intelligence tools then track whether those programs are actually working, measuring their impact on adherence rates and brand performance. The data loop is straightforward: launch a patient support initiative, measure whether patients on the program refill prescriptions more consistently, and adjust the program based on what the numbers show.
Monitoring Drug Safety After Approval
Analytics doesn’t stop once a drug is on pharmacy shelves. The FDA has a long history of using what it calls real-world data (RWD) and real-world evidence (RWE) to monitor the safety of approved drugs after they reach the market. Real-world data comes from sources patients interact with routinely: electronic health records, insurance claims, disease registries, and increasingly, digital health technologies like wearable devices and connected monitors.
Real-world evidence is what you get when you analyze that data for clinical insights, specifically about how a drug performs outside the controlled environment of a clinical trial. In trials, patients are carefully selected and closely monitored. In the real world, drugs are taken by a much broader population, including older patients, people with multiple conditions, and those on other medications. Analytics applied to RWD can surface safety signals that trials were too small or too short to detect, such as rare side effects that only appear after months of use or interactions with commonly prescribed drugs.
For pharmaceutical companies, this post-market surveillance is both a regulatory obligation and a strategic tool. Demonstrating strong real-world outcomes can support label expansions, where a drug is approved for additional conditions beyond its original indication. It can also strengthen a company’s position in negotiations with insurers, who increasingly want evidence that a drug works not just in trials but in everyday clinical practice.